Aflibercept in the Treatment of Metastatic Colorectal Cancer
Open accessAbstract
Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic colorectal cancer, and at present is the only antiangiogenesis agent approved for the treatment of this cancer. Aflibercept is a novel angiogenesis-targeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. Here we review the role of angiogenesis in the tumorigenesis of colorectal cancer, strategies for targeting angiogenesis, and the clinical development of aflibercept.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Aflibercept binds to VEGF ligands to prevent binding to endogenous receptors.
“Afilbercept binds to VEGF ligands to prevent binding to endogenous receptors [52].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,708 · see citing works
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · see citing works
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752 · see citing works
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,606 · see citing works
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · see citing works
Siegel, R. L., Ward, E., Brawley, O. W., & Jemal, A. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20121 · Cited by 4,075 · see citing works
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931 · see citing works
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,010 · see citing works
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · see citing works
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · see citing works
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606 · see citing works
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · see citing works
Ychou, M., Boige, V., Pignon, J., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.-M., Saint‐Aubert, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0597 · Cited by 2,086 · see citing works
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · see citing works
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,962 · see citing works
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · see citing works
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J., Schrama, J. G., Erdkamp, F., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,330 · see citing works
Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265 · see citing works
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., & Shibuya, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9349 · Cited by 1,063 · see citing works
VEGF-receptor signal transduction
Cross, M. J., Dixelius, J., Matsumoto, T., & Claesson, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00193-2 · Cited by 864 · see citing works
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850 · see citing works
Fuchs, C. S., Marshall, J. L., Mitchell, E. P., Wierzbicki, R. F., Ganju, V., Jeffery, M., Schulz, J. J., Richards, D., Soufi‐Mahjoubi, R., Wang, B. X., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3357 · Cited by 849 · see citing works
Prewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 660 · see citing works
Allegra, C. J., Yothers, G., O’Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0855 · Cited by 590 · see citing works
Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O’Bryant, C. L., Chow, L. Q. M., Serkova, N. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7537 · Cited by 551 · see citing works
Congenital Hereditary Lymphedema Caused by a Mutation That Inactivates VEGFR3 Tyrosine Kinase
Irrthum, A., Karkkainen, M. J., Devriendt, K., Alitalo, K. K., & Vikkula, M. (2000) · The American Journal of Human Genetics · doi:10.1086/303019 · Cited by 428 · see citing works
Saltz, L. B., Lenz, H., Kindler, H. L., Höchster, H. S., Wadler, S., Hoff, P. M., Kemeny, N. E., Hollywood, E. M., Gönen, M., Quinones, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0949 · Cited by 424 · see citing works
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
Karkkainen, M. J., & Petrova, T. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203855 · Cited by 424 · see citing works
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356 · see citing works
Molecular basis of angiogenesis and cancer
Tonini, T., Rossi, F., & Claudio, P. P. (2003) · Oncogene · doi:10.1038/sj.onc.1206816 · Cited by 344 · see citing works
Management of hypertension in angiogenesis inhibitor-treated patients
Izzedine, H., Éderhy, S., Goldwasser, F., Soria, J., Milano, G. A., Cohen, A. A., Khayat, D., & Spano, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn713 · Cited by 344 · see citing works
Takahashi, Y. (1997) · Archives of Surgery · doi:10.1001/archsurg.1997.01430290087018 · Cited by 329 · see citing works
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Ring, L. E., New, T. N., Zabski, S. M., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398399 · Cited by 312 · see citing works
Zeng, H., Dvorak, H. F., & Mukhopadhyay, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103213200 · Cited by 292 · see citing works
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
Murukesh, N., Dive, C., & Jayson, G. C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605483 · Cited by 235 · see citing works
Lockhart, A. C., Rothenberg, M. L., Dupont, J., Cooper, W., Chevalier, P., Sternas, L. A., Buzenet, G., Koehler, E., Sosman, J. A., Schwartz, L. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9237 · Cited by 232 · see citing works
Self-citationCascinu, S., Staccioli, M. P., Gasparini, G. M., Giordani, P., Catalano, V., Ghiselli, R., Rossi, C., Baldelli, A. M., Graziano, F., Saba, V., et al. (2000) · PubMed · Cited by 208 · see citing works
Hecht, J. R., Trarbach, T., Jaeger, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba3 · Cited by 201 · see citing works
Hecht, J. R., Trarbach, T., Hainsworth, J. D., Major, P. P., Jäger, E., Wolff, R. A., Lloyd-Salvant, K., Bodoky, G., Pendergrass, K. B., Berg, W. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4496 · Cited by 177 · see citing works
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
Chu, E. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.05.005 · Cited by 130 · see citing works
Sobrero, A. F., Ackland, S. P., Clarke, S. J., Pérez-Carrión, R., Chiarra, S., Gapski, J., Mainwaring, P. N., Langer, B., & Young, S. (2009) · Oncology · doi:10.1159/000229787 · Cited by 117 · see citing works
Ramucirumab (IMC-1121B): A Novel Attack on Angiogenesis
Spratlin, J. L., Mulder, K. E., & Mackey, J. R. (2010) · Future Oncology · doi:10.2217/fon.10.75 · Cited by 76 · see citing works
Angiotensin-Converting Enzyme Inhibitors for Bevacizumab-Induced Hypertension
Dinçer, M., & Altundağ, K. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h244 · Cited by 68 · see citing works
Clinical Applications of VEGF-Trap (Aflibercept) in Cancer Treatment
Teng, L., Jin, K., He, K., Zhang, J., Wang, H., & Cao, J. (2010) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(10)70097-6 · Cited by 53 · see citing works
Cutsem, E. V., Tabernero, J. M., & Lakomý, R. (2011) · Annals of Oncology · Cited by 48 · see citing works
Köhne, C.-H., Bajetta, E., Lin, E. H., Valle, J. W., Cutsem, E. V., Hecht, J. R., Moore, M., Germond, C. J., Meinhardt, G., & Jacques, C. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4033 · Cited by 47 · see citing works
Tang, P. A., Cohen, S. J., Bjarnason, G. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4027 · Cited by 37 · see citing works
Anti-Angiogenic Treatment of Gastrointestinal Malignancies
Salmon, J. S., Lockhart, A. C., & Berlin, J. D. (2005) · Cancer Investigation · doi:10.1080/07357900500360024 · Cited by 18 · see citing works
Self-citationRixe, O., Verslype, C., Khayat, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3557 · Cited by 16 · see citing works
Ychou, M., Bouché, O., Thézenas, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.e14002 · Cited by 11 · see citing works
Hecht, J. R., Yoshino, T., Mitchell, E. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3532 · Cited by 9 · see citing works
Townsley, C. A., Siu, L. L., Pedro-Salcedo, M. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2536 · Cited by 8 · see citing works
Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma.
de Groot, J., Cloughesy, T. F., Lieberman, F. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2043 · Cited by 7 · see citing works
Samson, B., Latreille, J., Nguyen, N. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.4_suppl.545 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Examination of the foreign body response to biomaterials by nonlinear intravital microscopy
Dondossola, E., Holzapfel, B. M., Alexander, S., Filippini, S., Hutmacher, D. W., & Friedl, P. (2016) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0007 · Cited by 215 · see citing works
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130 · see citing works
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87 · see citing works
- Authors
- Wang, T.-F., & Lockhart, A. C.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Lockhart, Albert Craig
- Venue
- Clinical Medicine Insights: Oncology
- Publisher
- SAGE Publications
- Published
- 2012-01
- Volume
- 6
- Pages
- 19-30
- ISSN
- 1179-5549 (ISSN-L)
- PMC
- PMC3256978
- OpenAlex
- W1967397018
- Cited by
- 44
- References
- 58
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 1 · 2016: 8 · 2015: 4 · 2014: 3 · 2013: 7 · 2012: 5
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Clinical Medicine Insights Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- aflibercept, metastatic colorectal cancer, angiogenesis, anti-angiogenic therapy, bevacizumab, VEGF receptor inhibition, carcinogenesis, clinical development, progression-free survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
